SEC set to review Covaxin trial data for use in children

SEC set to review Covaxin trial data for use in children Bharat Biotech has completed the Phase 2/3 trials of COVID-19 vaccine Covaxin for use in children under 18 years of age. https://ift.tt/eA8V8J